AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 527277: Pentanoic acid, 4-methyl, 2-iodoethyl ester

Chemical compound data from PubChem database. IUPAC Name: 2-iodoethyl 4-methylpentanoate. Molecular Formula: C8H15IO2. Molecular Weight: 270.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Transcriptional transactivation by selected short random peptides attached to lexA-GFP fusion proteins

Background
          Transcriptional transactivation is a process with remarkable tolerance for sequence diversity and structural geometry. In studies of the features that constitute transactivating functions, acidity has remained one of the most common characteristics observed among native activation domains and activator peptides.
        
        
          Results
          We performed a deliberate search of random peptide libraries for peptides capable of conferring transcriptional transactivation on the lexA DNA binding domain. Two libraries, one composed of C-terminal fusions, the other of peptide insertions within the green fluorescent protein structure, were used. We show that (i) peptide sequences other than C-terminal fusions can confer transactivation; (ii) though acidic activator peptides are more common, charge neutral and basic peptides can function as activators; and (iii) peptides as short as 11 amino acids behave in a modular fashion.
        
        
          Conclusions
          These results support the recruitment model of transcriptional activation and, combined with other studies, suggest the possibility of using activator peptides in a variety of applications, including drug development work.
Patent AT-E399782-T1: [Translated] PHENYLCARBOXYRAMIDE COMPOUNDS SUITABLE FOR THE TREATMENT OF PAIN

The present invention discloses compounds of formula: (I) (II) where Ar 1 , Ar 2 , X, R 1 , R 2 , R 3 , m, and n are disclosed herein or a pharmaceutically acceptable salt thereof (a "Phenylene Compound"); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Phenylene Compound.
2015 CMHS Uniform Reporting System (URS) Table for Indiana

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Indiana. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 529150: 1-Heptadecanol, TMS

Chemical compound data from PubChem database. IUPAC Name: N-trimethylsilylheptadecan-1-amine. Molecular Formula: C20H45NSi. Molecular Weight: 327.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
4.21b Type of care offered in facilities with Opioid Treatment Programs (OTPs), by facility operation and primary focus of facility: 2011. Percent

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing the type of care offered in facilities with Opioid Treatment Programs (OTPs), by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Compound 527768: 2,2-Dichloroethyl propionate

Chemical compound data from PubChem database. IUPAC Name: 2,2-dichloroethyl propanoate. Molecular Formula: C5H8Cl2O2. Molecular Weight: 171.02. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Youth Mental Health Tables (Prevalence Estimates) - 2.1 to 2.14

These detailed tables present totals and prevalence estimates of mental health related issues among adolescents aged 12 to 17 from the 2012 National Survey on Drug Use and Health (NSDUH). Tables with data on ayouths include measures on mental health service utilization, MDE, treatment for depression (among youths with MDE), and co-occurrence of mental disorders with substance use or with substance use disorders. Results are provided by age group, gender, race/ethnicity, education level, county type, poverty level, insurance status, overal health, and geographic area. Comparisons are made between 2012 and 2011.
Adolescent Births

This dataset contains California’s adolescent birth rate (ABR) by county, age group and race/ethnicity using aggregated years 2014-2016. The ABR is calculated as the number of live births to females aged 15-19 divided by the female population aged 15-19, multiplied by 1,000. Births to females under age 15 are uncommon and thus added to the numerator (total number of births aged 15-19) in calculating the ABR for aged 15-19. The categories by age group are aged 18-19 and aged 15-17; births occurring to females under aged 15 are added to the numerator for aged 15-17 in calculating the ABR for this age group. The race and ethnic groups in this table utilized five mutually exclusive race and ethnicity categories. These categories are Hispanic and the following Non-Hispanic categories of Multi-Race, Black, American Indian (includes Eskimo and Aleut), Asian and Pacific Islander (includes Hawaiian) combined, and White. Note that there are birth records with missing race/ethnicity or categorized as “Other” and not shown in the dataset but included in the ABR calculation overall.
Managing Obstetric Emergencies and Trauma (MOET) structured skills training in Armenia, utilising models and reality based scenarios

Background
          Mortality rates in Western Europe have fallen significantly over the last 50 years. Maternal mortality now averages 10 maternal deaths per 100,000 live births but in some of the Newly Independent States of the former Soviet Union, the ratio is nearly 4 times higher. The availability of skilled attendants to prevent, detect and manage major obstetric complications may be the single most important factor in preventing maternal deaths. A modern, multidisciplinary, scenario and model based training programme has been established in the UK (Managing Obstetric Emergencies and Trauma (MOET)) and allows specialist obstetricians to learn or revise the undertaking of procedures using models, and to have their skills tested in scenarios.
        
        
          Methods
          Given the success of the MOET course in the UK, the organisers were keen to evaluate it in another setting (Armenia). Pre-course knowledge and practice questionnaires were administered. In an exploratory analysis, post-course results were compared to pre-course answers obtained by the same interviewer.
        
        
          Results
          All candidates showed an improvement in post-course scores. The range was far narrower afterwards (167–188) than before (85–129.5). In the individual score analysis only two scenarios showed a non-significant change (cord prolapse and breech delivery).
        
        
          Conclusion
          This paper demonstrates the reliability of the model based scenarios, with a highly significant improvement in obstetric emergency management. However, clinical audit will be required to measure the full impact of training by longer term follow up. Audit of delays, specific obstetric complications, referrals and near misses may all be amenable to review.
Safety of a new extensively hydrolysed formula in children with cow's milk protein allergy: a double blind crossover study

Background
          Formulae for infants with cow's milk protein allergy (CMA) should be based on extensively hydrolysed protein. 'Extensively' however is not strictly defined. Differences in molecular weight and peptide chain length may affect its clinical outcome. We studied the safety of a new extensively hydrolysed casein based formula (Frisolac Allergycare®: FAC) for children with IgE mediated CMA.
        
        
          Methods
          Thirty children, aged 1.5 – 14.8 years old (median 4.9 years) with persistent CMA were enrolled in this double-blind reference product (Nutramigen®: NUT) controlled crossover study. All had positive skin prick tests (SPT) and IgE mediated allergy, showing immediate reactions after ingestion of small amounts of milk. Twenty-five children also had positive radio allergen sorbent tests (RAST) to cow's milk. Formulae provided consisted of 80% elementary formula in combination with 20% reference or test product. Crossover periods lasted for two weeks. From both products molecular weight (MALDI-TOF method and HPLC) and peptide chain length distribution (adapted Edman degradation) were determined.
        
        
          Results
          Maximum molecular weights of NUT and FAC are 2.1 and 2.56 kDa, respectively. The contribution of free amino acids and small peptides <0.5 kDa is 46% for FAC and 53% for NUT. About 50% of the protein fraction of both products consists of peptides longer than four amino acids. Three children did not complete the study. The other children all tolerated FAC very well; no adverse reactions were reported.
        
        
          Conclusions
          The new extensively hydrolysed casein-based formula (FAC) can safely be used in children with IgE mediated cow's milk allergy.
Compound 528641: Trimethylsilyl 3-methyl-2-[(trimethylsilyl)oxy]pentanoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-methyl-2-trimethylsilyloxypentanoate. Molecular Formula: C12H28O3Si2. Molecular Weight: 276.52. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401785-T1: [Translated] DRINKING DEVICE FOR ANIMALS

An animal water trough having a cover structure which fits within the trough and preferably adapted to float on the surface of trough water to substantially cover the whole water surface area. Receptacles or channels are provided in the cover. Apertures, which communicate with the water trough, are provided in the channel walls to convey water from the trough into the receptacle or channel. Preferably, a substance dispenser is located in the cover, which feeds substances into the trough water.
United States COVID-19 County Level Data Sources - ARCHIVED

The Public Health Emergency (PHE) declaration for COVID-19 expired on May 11, 2023. As a result, the Aggregate Case and Death Surveillance System will be discontinued. Although these data will continue to be publicly available, this dataset will no longer be updated.

On October 20, 2022, CDC began retrieving aggregate case and death data from jurisdictional and state partners weekly instead of daily. 

This dataset includes the URLs that were used by the aggregate county data collection process that compiled aggregate case and death counts by county. Within this file, each of the states (plus select jurisdictions and territories) are listed along with the county web sources which were used for pulling these numbers. Some states had a single statewide source for collecting the county data, while other states and local health jurisdictions may have had standalone sources for individual counties. In the cases where both local and state web sources were listed, a composite approach was taken so that the maximum value reported for a location from either source was used. The initial raw data were sourced from these links and ingested into the CDC aggregate county dataset before being published on the COVID Data Tracker.
Denver: Drug-Related Emergency Department Visits, 2004-2011 - Seeking Detox

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving patients seeking detox in the Denver metropolitan area, covering 2004-2011. This includes nonemergency requests made through the ED for admission to detoxification unit, visits to obtain medical clearance before being incarcerated, and acute emergencies where an individual is experiencing withdrawal symptoms and requests detox. These estimates do not include patients who seek or enter the hospital\'s detox unit through other avenues.
Compound 527782: 4-Penten-2-ol, benzoate

Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl benzoate. Molecular Formula: C12H14O2. Molecular Weight: 190.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525156: Glycerol-pentapropylene glycol ether, triacetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-(2,3-diacetyloxypropoxy)propoxy]propoxy]propoxy]propoxy]propyl acetate. Molecular Formula: C24H44O11. Molecular Weight: 508.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Thyrotropin alfa

Thyrogen (thyrotropin alfa) is a prescription medication that mimics thyroid-stimulating hormone to help diagnose or treat thyroid conditions, such as in thyroid cancer patients preparing for radioactive iodine therapy. It's administered as an intramuscular injection, available as a lyophilized powder for solution. Manufactured by Genzyme Corporation. This information was generated using AI and is provided for informational and research purposes only.
NNDSS - Table II. Tetanus to Vibriosis

NNDSS - Table II. Tetanus to Vibriosis - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable.    NP: Nationally notifiable but not published.    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. �� Any species of the family Vibrionaceae, other than toxigenic Vibrio cholerae O1 or O139.
Infant Adoption Awareness Training Program

On October 17, 2000 the U.S. Congress, under Public Law 103-310, amended the Public Health Services Act to authorize specific activities pertaining to Infant Adoption Awareness (title XII, Subtitle A). The legislation requires the Secretary of the Department of Health and Human Services (DHHS) to award grants to adoption organizations to develop and implement programs to train the designated staff of eligible health centers in providing adoption information and referral to pregnant women on an equal basis with all other courses of action included in nondirective counseling for pregnant women. The term "eligible health centers" means public and nonprofit private entities that provide health services to pregnant women. The legislation also requires the Secretary to establish a set of best-practice guidelines to which the DHHS-funded training programs will adhere in providing training to staff of eligible health centers.

In response to these legislative requirements, the Department of Health and Human Services has developed the following "best-practice" guidelines to be followed by recipients of cooperative agreements in developing curriculum and providing training to implement the Infant Adoption Awareness Training Program (IAATP). This "best-practice" guideline is critical for attaining the primary IAATP goal- enhancing the ability of health center personnel to provide adoption information and referral on an equal basis with all other courses of action included in nondirective counseling for pregnant women.

Consistent with the intent of the legislation, these guidelines were developed in consultation with 29 experts in the fields of adoption, child welfare, health services, medicine, law, and adoption counseling, as well as adoptive parents.

Training Goals

Basic Skills

Curriculum

Training Structure

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400943-T1: [Translated] BINARY TREE METHOD AND SYSTEM FOR MULTIPLEX SCHEDULE

Chemical patent from PubChem database. Patent Number: AT-E400943-T1. Title: Improved Chemical Process. Filing Date: 1995-03-17. Inventors: Smith, John A., Johnson, Mary B.. Abstract: An improved chemical process is disclosed, featuring enhanced yield, reduced reaction time, and improved environmental profile compared to conventiona... IPC Classifications: C12N, C12P, A61K. This patent covers 27 claims related to 7 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 530095: 2-Thiohistidine, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-(2-sulfanylideneimidazol-4-yl)-2-(trimethylsilylamino)propanoate. Molecular Formula: C12H23N3O2SSi2. Molecular Weight: 329.57. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Clinical review: Splanchnic ischaemia

Inadequate splanchnic perfusion is associated with increased morbidity and mortality, particularly if liver dysfunction coexists. Heart failure, increased intra-abdominal pressure, haemodialysis and the presence of obstructive sleep apnoea are among the multiple clinical conditions that are associated with impaired splanchnic perfusion in critically ill patients. Total liver blood flow is believed to be relatively protected when gut blood flow decreases, because hepatic arterial flow increases when portal venous flow decreases (the hepatic arterial buffer response [HABR]). However, there is evidence that the HABR is diminished or even abolished during endotoxaemia and when gut blood flow becomes very low. Unfortunately, no drugs are yet available that increase total hepato-splanchnic blood flow selectively and to a clinically relevant extent. The present review discusses old and new concepts of splanchnic vasoregulation from both experimental and clinical viewpoints. Recently published trials in this field are discussed.
Quality and methods of developing practice guidelines

Background
          It is not known whether there are differences in the quality and recommendations between evidence-based (EB) and consensus-based (CB) guidelines. We used breast cancer guidelines as a case study to assess for these differences.
        
        
          Methods
          Five different instruments to evaluate the quality of guidelines were identified by a literature search. We also searched MEDLINE and the Internet to locate 8 breast cancer guidelines. These guidelines were classified in three categories: evidence based, consensus based and consensus based with no explicit consideration of evidence (CB-EB). Each guideline was evaluated by three of the authors using each of the instruments. For each guideline we assessed the agreement among 14 decision points which were selected from the NCCN (National Cancer Comprehensive Network) guidelines algorithm. For each decision point we recorded the level of the quality of the information used to support it. A regression analysis was performed to assess if the percentage of high quality evidence used in the guidelines development was related to the overall quality of the guidelines.
        
        
          Results
          Three guidelines were classified as EB, three as CB-EB and two as CB. The EB guidelines scored better than CB, with the CB-EB scoring in the middle among all instruments for guidelines quality assessment. No major disagreement in recommendations was detected among the guidelines regardless of the method used for development, but the EB guidelines had a better agreement with the benchmark guideline for any decision point. When the source of evidence used to support decision were of high quality, we found a higher level of full agreement among the guidelines' recommendations. Up to 94% of variation in the quality score among guidelines could be explained by the quality of evidence used for guidelines development.
        
        
          Conclusion
          EB guidelines have a better quality than CB guidelines and CB-EB guidelines. Explicit use of high quality evidence can lead to a better agreement among recommendations. However, no major disagreement among guidelines was noted regardless of the method for their development.
Compound 526932: 2-Ethylthienothiophene

Chemical compound data from PubChem database. IUPAC Name: 2-ethylthieno[2,3-c]thiophene. Molecular Formula: C8H8S2. Molecular Weight: 168.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401402-T1: [Translated] PROTEINS INTERACTING WITH SYNDEKAN AND THEIR USE

The invention relates to the identification of a new protein that binds to the cytoplasmic domain of syndecan. This new protein, denominated as "syntenin", contains 298 amino acids and is characterized by a tandem repeat of PDZ-domains that reacts with the C-terminal amino acid sequence of syndecans. The amino-terminal region of syntenin further comprises five tyrosine residues whereas no tyrosine residues are present in the remaining part of the protein. The present invention further discloses a nucleic acid encoding syntenin, a method to screen for components interfering with the syndecan-syntenin interaction, a method for diagnosing Alzheimer's disease, inflammatory diseases, and malignancies and a pharmaceutical composition for healing the latter diseases.
Patent AT-E401815-T1: [Translated] COFFEE MACHINE

This invention relates to an automatic coffee machine (1) designed with the inspiration of conventional cooking methods, used to cook Turkish coffee with its traditional flavor and consistency in a short period of time, suitable to be used in homes and especially in crowded places such as hotels, restaurants or cafes, wherein means are provided to improve the delivering of water from the water reservoir (2) to the cooking chambers (3), where Turkish coffee is prepared, by means of pumps (4).